Litcius/Paper detail

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan, Silvio Danese, Edward V. Loftus, Séverine Vermeire, Stefan Schreiber, Timothy E. Ritter, Ronald Fogel, Rajiv Mehta, Sandeep Nijhawan, Radosław Kempiński, Rafał Filip, Ihor Hospodarskyy, Ursula Seidler, Frank Seibold, Ian Beales, Hyo Jong Kim, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chia‐Hsiang Hsueh, Chantal Tasset, R. Besuyen, Mamoru Watanabe, William J. Sandborn, Gerhard Rogler, Toshifumi Hibi∥, Laurent Peyrin‐Biroulet

2021The Lancet438 citationsDOI

Topics & Concepts

MedicineVedolizumabUlcerative colitisPlaceboInternal medicineMaintenance therapyClinical endpointClinical trialGastroenterologyRegimenSurgeryChemotherapyDiseasePathologyAlternative medicineInflammatory Bowel DiseaseSpondyloarthritis Studies and TreatmentsNatural Compounds in Disease Treatment